- Home
- RFMZ vs EDIT Comparison
RFMZ vs EDIT Comparison
Compare RFMZ & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFMZ
- EDIT
- Stock Information
- Founded
- RFMZ 2021
- EDIT 2013
- Country
- RFMZ United States
- EDIT United States
- Employees
- RFMZ N/A
- EDIT N/A
- Industry
- RFMZ Trusts Except Educational Religious and Charitable
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RFMZ Finance
- EDIT Health Care
- Exchange
- RFMZ Nasdaq
- EDIT Nasdaq
- Market Cap
- RFMZ 339.7M
- EDIT 327.0M
- IPO Year
- RFMZ N/A
- EDIT 2016
- Fundamental
- Price
- RFMZ $14.09
- EDIT $2.66
- Analyst Decision
- RFMZ
- EDIT Buy
- Analyst Count
- RFMZ 0
- EDIT 13
- Target Price
- RFMZ N/A
- EDIT $9.38
- AVG Volume (30 Days)
- RFMZ 76.6K
- EDIT 2.3M
- Earning Date
- RFMZ 01-01-0001
- EDIT 11-04-2024
- Dividend Yield
- RFMZ 7.43%
- EDIT N/A
- EPS Growth
- RFMZ N/A
- EDIT N/A
- EPS
- RFMZ 0.65
- EDIT N/A
- Revenue
- RFMZ N/A
- EDIT $61,759,000.00
- Revenue This Year
- RFMZ N/A
- EDIT N/A
- Revenue Next Year
- RFMZ N/A
- EDIT N/A
- P/E Ratio
- RFMZ $21.49
- EDIT N/A
- Revenue Growth
- RFMZ N/A
- EDIT 150.95
- 52 Week Low
- RFMZ $11.28
- EDIT $2.59
- 52 Week High
- RFMZ $14.57
- EDIT $11.69
- Technical
- Relative Strength Index (RSI)
- RFMZ 45.61
- EDIT 35.77
- Support Level
- RFMZ $14.13
- EDIT $3.07
- Resistance Level
- RFMZ $14.30
- EDIT $3.38
- Average True Range (ATR)
- RFMZ 0.13
- EDIT 0.23
- MACD
- RFMZ 0.03
- EDIT -0.03
- Stochastic Oscillator
- RFMZ 57.14
- EDIT 8.64
About RFMZ RiverNorth Flexible Municipal Income Fund II Inc.
RiverNorth Flex Muni Income Fund II Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.